The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Spin-out Company

8 Jun 2012 07:00

RNS Number : 9464E
Frontier IP Group plc
08 June 2012
 



 

AIM: FIPP

 

FRONTIER IP GROUP PLC

("Frontier IP" or "the Group")

 

First Spin-out Company

with

the University of Central Lancashire

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce that it has agreed a collaboration with the University of Central Lancashire ("UCLan") to create and develop a new spin-out company from UCLan's Silicate Research Unit. The Group will provide advisory services and support in return for a 30% stake in the spin-out company and it is intended that Frontier IP will receive a share of licensing revenues.

 

The new spin-out company is being formed to license and commercialise the process which the Silicate Research Unit has developed to transform waste materials into a highly durable and functional material with applications in the construction industry. Waste materials that can be converted include ceramics, incinerated waste and lead glass. The new material has a wide range of uses including interior and exterior wall cladding, flooring, bricks and work surfaces and is also itself wholly recyclable. The Silicate Research Unit believes that the new material offers an attractive option for architects and designers, combining sustainability with the ability to customise the design and finish of the product. The product has recently been exhibited at a number of international design shows where it was well received.

 

UCLan is committed to delivering high impact research which has commercial potential. It has a well established research reputation within the areas of Business, Health, Humanities and Science which has lead to the emergence of specific research centres in a number of areas including Nuclear, and Nanotechnology and Bioengineering. In the latest Research Assessment Exercise*, all 17 of the subject areas UCLan submitted were rated as containing research of international excellence while 11 areas were assessed to be undertaking research which is world-leading.

 

Neil Crabb, Chairman of Frontier IP, said,

 

"This collaboration with the University of Central Lancashire represents an exciting new opportunity for Frontier IP. We have in-depth experience in commercialising university IP and we look forward to working with UCLan to maximise the potential of the Silicate Research Unit's cutting-edge product, which offers a 100% recyclable option to designers and architects across a broad range of applications."

 

Professor Margaret Bruce, Pro Vice Chancellor for Engagement at UCLan commented on the relationship,

 

"This is an important development for UCLan. By working together with our academics and Frontier IP, we will be able to capitalise on the excellent research within the university and bring innovative products to market."

 

David Binns from the Silicate Research Unit added,

 

"We are delighted that our innovative research is being taken out into the wider world. Our new products have the potential to make a real difference in the sustainable use of previously problematic waste materials."

 

 

* conducted jointly by the Higher Education Funding Council for England, the Scottish Funding Council, the Higher Education Funding Council for Wales and the Department for Employment and Learning, Northern Ireland and published in 2008

 

 

Enquiries

Company website: www.frontierip.co.uk

 

Frontier IP Group Plc

T: 0131 220 9491

Neil Crabb, Executive Chairman

Fairfax IS PLC

T: 020 7598 5368

(Nominated Adviser and Broker)

Stuart Gledhill / Katy Birkin

Biddicks

T: 020 3178 6378

Katie Tzouliadis / Sophie McNulty

 

 

 

Notes to Editor:

 

The University of Central Lancashire ("UCLan") offers over 500 undergraduate programmes and 180 postgraduate courses. The University has an established research reputation within the areas of Business, Health, Humanities and Science. In the Research Assessment Exercise 2008, all 17 subject areas submitted were rated as containing research of international excellence while 11 areas were assessed to be undertaking research which is world-leading. With approximately 32,000 students, the University indirectly contributes close to £250 million into the regional economy every year. UCLan is currently in the process of spending more than £120 million on new buildings and facilities to support teaching, learning and leisure activities.

 

Frontier IP Group Plc ("Frontier IP") specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGGVVNRGZZM
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.